We offer an unrivalled client experience, with a hands on, expert approach in everything we do.
Partner with Nemean. Get in touch to find out how to get started.
Our Team
Our focus is on driving value for you
Dr Thomas Duthy
Founder & Chief Executive Officer
Prior to establishing Nemean, Tom was the Global Head of Investor Relations & Corporate Development at Sirtex Medical Limited (ASX:SRX) and a member of the Senior Leadership Team. Sirtex is a global medical device player focused on the sale and development of innovative interventional oncology products and was an S&P/ASX 200 Company (also a Top 100 Company from 2015-2017) prior to it being sold. In financial year 2018, the Company recorded revenues of $219 million, an underlying Net Profit After Tax of $41.5 million and operating cash flows of $56.0 million.
In January 2018, it was announced that Sirtex was to be acquired by Varian Medical Systems (NYSE:VAR) for A$1.6 billion. In May 2018, a consortium led by CDH Investments, a China-based alternative asset manager with over US$20 billion under management, announced a superior takeover proposal for Sirtex, valuing the company at A$1.9 billion. The transaction was successfully completed in September 2018. This corporate deal represented the largest ever medical device transaction in Australia by value and was a Top Ten Med Tech M&A deal globally over the previous 12 months. The exit price of $33.60 per share represented a ten year average annual return of over 27% for investors.
Tom was instrumental in developing corporate strategies designed to maximise shareholder value. This included expansion of the share register targeting US and European institutional investors, several group-wide restructuring plans, initiating and execution of share buy-backs, an active non-core asset divestment program and the assessment of M&A and other partnering opportunities to drive value.
Prior to Sirtex, Tom spent ten years as a leading sell-side Healthcare & Biotechnology analyst at Taylor Collison Limited, focused mainly on small cap companies. Tom developed this sector capability to become a major leader in terms of deal flow and returns. During this time, approximately $200 million in equity capital was raised for selected portfolio companies. Tom has previously advised leading ASX Healthcare & Biotechnology companies including Sirtex Medical (ASX:SRX), Biota Holdings Limited (ASX:BTA), Ellex Medical Lasers (ASX:ELX), CogState (ASX:CGS) and AtCor Medical Holdings (ASX:ACG). Tom also held an RG146 certification to provide financial advice to retail clients during this period.
Tom holds a PhD (with commendation) from the University of Adelaide and an MBA from Deakin University. He is a Member of the Australian Institute of Company Directors (MAICD) and the Australasian Investor Relations Association (AIRA).
Tom is currently a Non-Executive Director of the Liver Foundation (Australia).
Tim Case
Director, Corporate Development
Prior to joining Nemean, Tim was the Senior Commercial Manager at RetireAustralia, Australia’s largest private retirement and aged care operator. As a member of the Senior Leadership Team, Tim was instrumental in the formation and execution of the company’s aged care strategy. Tim had commercial oversight of a new community care business and developed an innovative private aged care funding model new to the Australian market. Tim’s role also included M&A opportunity identification, due diligence, investor presentations, financial modelling and reporting to the Board of Directors on new growth strategies.
Before joining RetireAustralia Tim was an Equity Analyst at Australian Ethical Investment (ASX:AEF; +$3.5 billion funds under management) for nearly five years covering ASX listed medical technology, healthcare and high growth industrial companies. Tim was a member of an investment team that has delivered consistent investment outperformance (flagship Australian Shares Fund has delivered +10% p.a. net of fees over 10 years). During his time at Australian Ethical Investment Tim evaluated investment opportunities through a fundamental research process and applied rigorous investment criteria with a long term investment horizon. The role required Tim to establish strong working relationships with company founders, senior company executives and associated Board members in order to assess current or potential investment opportunities. Additionally, Tim nurtured and grew Australian Ethical’s investment banking and broker relationships through direct dealings with institutional advisers and sell-side analysts.
Tim also has over 6 years of financial services experience in London including working at Royal Bank of Scotland and Merrill Lynch.
Tim is passionate about helping companies navigate the challenges faced in commercialising health care technology and is currently advising start-ups in the medical device and healthcare space on strategic, funding and operational matters.
Tim is a Chartered Financial Analyst® (CFA) charter holder.